𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis

✍ Scribed by J. F. Medina; E. Martínez-Ansó; J. J. Vázquez; J. Prieto

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
315 KB
Volume
25
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

seven patients (three women and four men, mean age 49 years) who had no histological or biochemical signs of liver disease (specimens were obtained at laparotomy for conditions not affecting the liver); Abbreviations: PBC, primary biliary cirrhosis; UDCA, ursodeoxycholic acid; AE, anion (3) a second control group referred to as the cirrhosis group, which exchanger; mRNA, messenger RNA; HCV, hepatitis C virus; PSC, primary sclerosing cholincluded 17 patients (8 women and 9 men; mean age 57 years) with angitis; Ig, immunoglobulin.

cirrhosis of two different etiologies, i.e., alcoholic cirrhosis and hepa-From the 1 Department of Internal Medicine and Liver Unit and the 2 Department of titis C virus (HCV)-induced cirrhosis; and (4) a third control group

📜 SIMILAR VOLUMES

Effect of pretransplantation ursodeoxych
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis
✍ Heathcote, E. Jenny ;Stone, Julie ;Cauch-Dudek, Karen ;Poupon, Raoul ;Chazouille 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 42 KB

As ursodeoxycholic acid (UDCA) delays the need for transplantation, this could result in patients with more comorbid disease, therefore more likely to have a worse outcome posttransplantation. The aim of this study is to compare posttransplantation outcome in patients who received UDCA versus placeb

The clinical effectiveness and safety of
The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis
✍ Edward P. Ambinder; Larry B. Cohen; Anita M. Wolke; Steven P. Field; Bernard Ade 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 404 KB

Primary biliary cirrhosis (PBC) is a chronic nonsuppurative, destructive cholangitis, whose etiology is unknown. Morbidity arises early from pruritus and later from hypercholesterolemia with xanthoma formation. Therapy is supportive and directed at the complications of cholestasis. Plasmapheresis ha

Oral budesonide in the treatment of pati
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid
✍ Paul Angulo; Roberta A. Jorgensen; Jill C. Keach; E. Rolland Dickson; Coleman Sm 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 1 views

Ursodeoxycholic acid (UDCA) is a safe and effective medical therapy for most patients with primary biliary cirrhosis (PBC). However, some patients show an incomplete response to UDCA therapy. Treatment with corticosteroids may be of benefit although at the expense of systemic side effects. Budesonid

Does antimitochondrial antibody status a
Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation
✍ W R Kim; J J Poterucha; R A Jorgensen; K P Batts; H A Homburger; E R Dickson; R 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 1 views

rum. 1 In the past decade, two treatment modalities have Approximately 5% to 10% of patients with features otherbeen shown to be effective in the treatment for PBC, dewise consistent with primary biliary cirrhosis (PBC) lack antipending on the stage of the disease. For patients with less mitochondri

Differences in the metabolism and dispos
Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis
✍ Pietro Invernizzi; Kenneth D. Setchell; Andrea Crosignani; Pier Maria Battezzati 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

The clinical effectiveness of ursodeoxycholate in the treatment of liver disease may be limited by its poor absorption and extensive biotransformation. Because in vitro and in vivo studies suggest that the more hydrophilic bile acid tauroursodeoxycholate has greater beneficial effects than ursodeoxy